Item 5. OTHER INFORMATION

Disclosure of 10b5-1 plans

On June 17, 2026, Marc E. Binda, our Chief Financial Officer and Treasurer, terminated a Rule 10b5-1 trading arrangement

that he had previously adopted in December 2025 for the sale from time to time of up to 23,368 shares of common stock. The trading

arrangement was intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and was scheduled

to expire on December 1, 2026.

On June 18, 2026, Hallie E. Kuhn, our Executive Vice President – Capital Markets and Co-Lead – Life Science, terminated a

Rule 10b5-1 trading arrangement that she had previously adopted in December 2025 for the sale from time to time of up to 2,574

shares of common stock. The trading arrangement was intended to satisfy the affirmative defense conditions of Securities Exchange

Act Rule 10b5-1(c) and was scheduled to expire on October 16, 2026.

On June 25, 2026, Hart Cole, our Co-President & Co-Regional Market Director – Seattle, terminated a Rule 10b5-1 trading

arrangement that he had previously adopted in December 2025 for the sale from time to time of up to 20,000 shares of common stock.

The trading arrangement was intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) and was

scheduled to expire on January 29, 2027.

During the three months ended June 30, 2026, no other officers or directors adopted or terminated any contract, instruction, or

written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or

any “non-Rule 10b5-1 trading arrangement.”